March 3 (Reuters) - Prometic Life Sciences Inc PLI.TO
* US FDA grants orphan drug designation to Prometic's PBI-4050 drug for the treatment of alström syndrome
* Prometic Life Sciences - currently investigating effects of PBI-4050 on multiple organs in as patients in ongoing, open label, phase 2, clinical study in UK Source text for Eikon: ID:nCNW5Ygt6a Further company coverage: PLI.TO